![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by geno on December 18, 2001, at 17:40:21
There will be a drug available called Escitalopram...It's called also
anti-shyness drug...It is in fact a SSRI.But according to Claude
Rifat's Theory it would be a good alternative for GHB in aspect of
Socialness...(He was said that Depression is an illness caused by
Anti-Social behaviour.).It is also very interesting that a drug
increasing socialness.It is not available yet...Research info as:
NEW ORLEANS, LA -- May 9, 2001 -- Escitalopram at 10 mg/day and 20
mg/day demonstrated greater improvement relative to placebo at
endpoint
than citalopram in a U.S.-conducted, Phase III clinical trial of
patients with major depressive disorder. Escitalopram, a single isomer
of citalopram and a more potent and selective serotonin reuptake
inhibitor (SSRI), showed consistent antidepressant effect across all
efficacy measures at 10/mg day, a lower dose than currently indicated
for any antidepressant of the SSRI class. This effective dose was
exceptionally well-tolerated. The data were presented in New Orleans
during a meeting of the American Psychiatric Association."Based on the data, escitalopram shows great promise as a first-line
treatment for major depression," said William Burke, MD, professor of
psychiatry at the University of Nebraska Medical School and lead
investigator of this study.In a randomized, double-blind, placebo-controlled, multicenter study,
491 patients with ongoing major depressive episodes were randomized
for
eight weeks to one of four trial arms: placebo, citalopram at 40
mg/day,
escitalopram at 10 mg/day and escitalopram at 20 mg/day. The male and
female outpatients ranged from 18 to 65 years of age.The Montgomery-Asberg Depression Rating Scale (MADRS), which was the
prospectively defined primary endpoint, showed that escitalopram at
both
10 mg/day and 20 mg/day doses significantly separated from placebo
beginning at week two and maintained that separation at all time
points.
On all other key outcome measures including the HAM-D, HAM-D item 1
and
CGI, escitalopram 10 and 20 mg/day statistically separated from
placebo
at either week one or two. At all time points, both escitalopram doses
produced greater changes on the primary endpoint (MADRS) than
citalopram
40 mg/day.Remarkably, there was no difference in the incidence of
discontinuations
due to adverse events between escitalopram 10 mg/day and placebo
treatment (4.2 percent vs. 2.5 percent), or between escitalopram 20
mg/day and citalopram treatment (10.4 percent vs. 8.8 percent).
Escitalopram at both doses was well-tolerated, with a low incidence of
adverse events such as nausea, diarrhea, insomnia and dry mouth.Dr. Burke noted that investigators have been especially pleased with
the
low discontinuation rates of escitalopram, and attribute it to its
high
tolerability.Certain chemicals in nature exist in two mirror-image forms, or
isomers,
which can be called right- and left-handed. Citalopram is a mixture of
two mirror-image structures, an S- and R-isomer. The left-handed form,
or S-isomer, is the active isomer in terms of its contribution to
citalopram's antidepressant effects, while the R-isomer does not
contribute to its antidepressant activity.Based on the clinical trial data, Forest Laboratories submitted a new
drug application (NDA) on March 23, 2001 to the U.S. Food and Drug
Administration seeking an indication for escitalopram for the
treatment
of depression.SOURCE: University of Nebraska Medical Center
Post a follow-up to this message--------------------------------------------------------------------------------
Google Home - Advertise with Us - Add Google to Your Site - News and Resources - Language Tools - Jobs, Press, Cool Stuff...©2001 Google
Posted by stjames on December 18, 2001, at 18:44:18
In reply to escitaloproam, posted by geno on December 18, 2001, at 17:40:21
Certain chemicals in nature exist in two mirror-image forms, or
isomers,
which can be called right- and left-handed. Citalopram is a mixture of
two mirror-image structures, an S- and R-isomer. The left-handed form,
or S-isomer, is the active isomer in terms of its contribution to
citalopram's antidepressant effects, while the R-isomer does not
contribute to its antidepressant activity.
The so called "least patentable difference". I would not hold my breath !
Posted by IsoM on December 19, 2001, at 3:03:31
In reply to escitaloproam, posted by geno on December 18, 2001, at 17:40:21
Seeing that this drug is Celexa but only the active form, not the combination of both right-handed & left-handed molecules. It would give the same benefits as Celexa does but with less side-effects, that's all.
> There will be a drug available called Escitalopram...It's called also
> anti-shyness drug...It is in fact a SSRI.But according to Claude
> Rifat's Theory it would be a good alternative for GHB in aspect of
> Socialness...(He was said that Depression is an illness caused by
> Anti-Social behaviour.).It is also very interesting that a drug
> increasing socialness.
>
> It is not available yet...Research info as:
>
> NEW ORLEANS, LA -- May 9, 2001 -- Escitalopram at 10 mg/day and 20
> mg/day demonstrated greater improvement relative to placebo at
> endpoint
> than citalopram in a U.S.-conducted, Phase III clinical trial of
> patients with major depressive disorder. Escitalopram, a single isomer
> of citalopram and a more potent and selective serotonin reuptake
> inhibitor (SSRI), showed consistent antidepressant effect across all
> efficacy measures at 10/mg day, a lower dose than currently indicated
> for any antidepressant of the SSRI class. This effective dose was
> exceptionally well-tolerated. The data were presented in New Orleans
> during a meeting of the American Psychiatric Association.
>
> "Based on the data, escitalopram shows great promise as a first-line
> treatment for major depression," said William Burke, MD, professor of
> psychiatry at the University of Nebraska Medical School and lead
> investigator of this study.
>
> In a randomized, double-blind, placebo-controlled, multicenter study,
> 491 patients with ongoing major depressive episodes were randomized
> for
> eight weeks to one of four trial arms: placebo, citalopram at 40
> mg/day,
> escitalopram at 10 mg/day and escitalopram at 20 mg/day. The male and
> female outpatients ranged from 18 to 65 years of age.
>
> The Montgomery-Asberg Depression Rating Scale (MADRS), which was the
> prospectively defined primary endpoint, showed that escitalopram at
> both
> 10 mg/day and 20 mg/day doses significantly separated from placebo
> beginning at week two and maintained that separation at all time
> points.
> On all other key outcome measures including the HAM-D, HAM-D item 1
> and
> CGI, escitalopram 10 and 20 mg/day statistically separated from
> placebo
> at either week one or two. At all time points, both escitalopram doses
> produced greater changes on the primary endpoint (MADRS) than
> citalopram
> 40 mg/day.
>
> Remarkably, there was no difference in the incidence of
> discontinuations
> due to adverse events between escitalopram 10 mg/day and placebo
> treatment (4.2 percent vs. 2.5 percent), or between escitalopram 20
> mg/day and citalopram treatment (10.4 percent vs. 8.8 percent).
> Escitalopram at both doses was well-tolerated, with a low incidence of
> adverse events such as nausea, diarrhea, insomnia and dry mouth.
>
> Dr. Burke noted that investigators have been especially pleased with
> the
> low discontinuation rates of escitalopram, and attribute it to its
> high
> tolerability.
>
> Certain chemicals in nature exist in two mirror-image forms, or
> isomers,
> which can be called right- and left-handed. Citalopram is a mixture of
> two mirror-image structures, an S- and R-isomer. The left-handed form,
> or S-isomer, is the active isomer in terms of its contribution to
> citalopram's antidepressant effects, while the R-isomer does not
> contribute to its antidepressant activity.
>
> Based on the clinical trial data, Forest Laboratories submitted a new
> drug application (NDA) on March 23, 2001 to the U.S. Food and Drug
> Administration seeking an indication for escitalopram for the
> treatment
> of depression.
>
> SOURCE: University of Nebraska Medical Center
> Post a follow-up to this message
>
>
>
> --------------------------------------------------------------------------------
> Google Home - Advertise with Us - Add Google to Your Site - News and Resources - Language Tools - Jobs, Press, Cool Stuff...
>
> ©2001 Google
Posted by Roo on December 19, 2001, at 9:01:58
In reply to Re: escitaloproam, posted by IsoM on December 19, 2001, at 3:03:31
Is it supposed to have less sexual side effects?
I notice they don't mention that...
Posted by IsoM on December 19, 2001, at 13:14:47
In reply to Re: escitaloproam, posted by Roo on December 19, 2001, at 9:01:58
I really can't say if it would have less sexual side-effects. Probably, as the side effects are supposed to come from the inactive form but maybe someone else can add some concrete about that.
> Is it supposed to have less sexual side effects?
> I notice they don't mention that...
Posted by Bill L on December 20, 2001, at 8:01:00
In reply to Re: escitaloproam » Roo, posted by IsoM on December 19, 2001, at 13:14:47
When I read the study results, there were less sexual side effects and also less daytime tiredness. As for the sexual side effects- the way it was worded was that it caused less "delayed orgasm".
> I really can't say if it would have less sexual side-effects. Probably, as the side effects are supposed to come from the inactive form but maybe someone else can add some concrete about that.
>
> > Is it supposed to have less sexual side effects?
> > I notice they don't mention that...
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.